Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 24, 2023

Safety and Antitumour Activity of the Anti–PD-1/CTLA-4 Bispecific Antibody Cadonilimab in Patients With Advanced Solid Tumours

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
Lancet Oncol 2023 Oct 01;24(10)1134-1146, X Gao, N Xu, Z Li, L Shen, K Ji, Z Zheng, D Liu, H Lou, L Bai, T Liu, Y Li, Y Li, Q Fan, M Feng, H Zhong, Y Huang, G Lou, J Wang, X Lin, Y Chen, R An, C Li, Q Zhou, X Huang, Z Guo, S Wang, G Li, J Fei, L Zhu, H Zhu, X Li, F Li, S Liao, Q Min, L Tang, F Shan, J Gong, Y Gao, J Zhou, Z Lu, X Li, J Li, H Ren, X Liu, H Yang, W Li, W Song, ZM Wang, B Li, M Xia, X Wu, J Ji

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading